

## **Mr. Vijendra Nalamothu:**



Dr. Vijendra Nalamothu is currently employed with Promius Pharma, a wholly owned subsidiary of Dr. Reddy's Laboratories, Inc., as the head of R&D. He spearheads the development of specialty branded dermatological products from concept to commercialization including various human clinical trials in US, Europe and India. In addition to North American branded products for Promius, he also develops branded dermatology products for various other countries wherein Dr. Reddy's markets products for various skin disorders. His interests include novel dosage form design and development of topical drug products, developing new disease models in animals, designing proof of concept studies in humans, animal toxicology studies, human clinical trials, process scale-up and manufacturing. Prior to joining Promius, he served as the Worldwide Head of Preclinical, Early Compound Assessment and Formulation Development for Sanofi-aventis' Dermatology.

Dr. Nalamothu received his Ph.D. in Pharmaceutical Sciences from University of the Sciences' Philadelphia College of Pharmacy. He has co/authored numerous publications and has patents for few of his inventions. He has presented his research findings in various international meetings. He is an invited speaker at various meetings and serves as a member of Society of Investigative Dermatology, American Association of Pharmaceutical Sciences and Controlled Release Society. Dr. Nalamothu also serves as a board member for Cornileius Pharmaceuticals and is a member of several pharmaceutical research focus and discussion groups.